Article source：Kexing Biopharm
Nov 06,2025
View：
1651 Recently, Kexing Biopharm (stock code: 688132.SH) has officially received marketing approval from the Georgian Medicines and Pharmaceutical Agency for its licensed-in generic product, Paclitaxel for Injection (Albumin-Bound). This marks the first marketing authorization for the product in the South Caucasus region, laying a solid foundation for subsequent deep penetration into the regional pharmaceutical market.
The albumin-bound paclitaxel, developed in collaboration with Haichang Biotech, has experienced rapid commercialization since its approval in the European Union last year. The stringent EU certification standards have effectively facilitated the product's entry into emerging markets, with recent approvals secured in multiple countries, including Peru, Oman, and Uruguay.
Looking ahead, Kexing Biopharm will continue to advance the overseas access and marketing efforts for its export products, while deepening collaborations with local healthcare systems to bring high-quality domestic medicines to more patients.
About Kexing
Kexing Biopharm (Stock Code: 688136.SH) is a multinational biopharmaceutical enterprise that engages in the R&D, manufacture and sales of innovative medicines of distinct modalities including recombinant proteins, antibodies, and targeted delivery therapies.
Through building cutting-edge technology platforms to advance the development of novel targeted therapies and drug delivery systems, Kexing Biopharm strives to address unmet clinical needs in the areas of oncology, autoimmune and antiviral treatment, creating a significant and meaningful positive impact on patients' lives.
By adhering to the platform development model driven by the twin engines of “Innovation & Internationalization”, Kexing Biopharm is committed to becoming a world leader in high-quality biopharmaceuticals, improving the health of patients worldwide.
BACK TO LIST
Sep 04,2026
